Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

38

Revenue 2017

Imbruvica

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Imbruvica was produced by Johnson & Johnson.

Roche pays $775m upfront to access Blueprint’s RET programme

Roche pays $775m upfront to access Blueprint’s RET programme

to currently available BTK inhibitors, such as Johnson &Johnson’s Imbruvica (ibrutinib).

EU grants approval for Venclyxto/Gazyvaro combo in CLL

EU grants approval for Venclyxto/Gazyvaro combo in CLL It also has to contend with the combination of AbbVie’s Imbruvica (ibrutinib) plus Gazyvaro, which became the first chemo-free option for first-line CLL therapy last year.

AZ revenues rise, but it says coronavirus could hit 2020

AZ revenues rise, but it says coronavirus could hit 2020 Recently-approved for a new chronic lymphocytic leukaemia (CLL) indication, AZ’s rival to Johnson &Johnson’s blockbuster BTK inhibitor Imbruvica (ibrutinib) – Calquence (acalabrutinib) – also gathered momentum and contributed $56m in

FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma Other treatment options for advanced MCL include BeiGene’s recently approved BTK inhibitor Brukinsa (zanubrutinib) and AbbVie/Johnson &Johnson’s established BTK inhibitor Imbruvica (ibrutinib).

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

Skyrizi, Rinvoq help AbbVie weather Humira slowdown Outside its critical immunology franchise there were also gains for blood cancer therapy Imbruvica (ibrutinib), up almost 29% to $1.3bn, as well as a $251m contribution from newer therapy Venclexta

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics